Detection of HPV types and neutralizing antibodies in gansu province, China

Journal of Medical Virology

Volumn 81, Issue 4, 2009, Pages 693-702

  Wu, Xueling ^a   Zhang, Chuntao ^a   Feng, Shuxian ^b   Liu, Chunyu ^a   Li, Yanqin ^b   Yang, Yongxiu ^c   Gao, Jun ^c   Li, Hongfang ^c   Meng, Shufang ^a   Li, Ping ^c   Zhang, Yunzhong ^c   Hu, Xuemei ^c   Wu, Xiaolu ^c   Lin, Lin ^a   Li, Xun ^c   Wang, Youchun ^a  

^a NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^b LANZHOU GENERAL HOSPITAL   (China)

^c LANZHOU UNIVERSITY   (China)

Author keywords

DNA; HPV; Neutralizing antibody; Pseudovirus; Type

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS DNA;

ADULT; ARTICLE; CHINA; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 68; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; UTERINE CERVIX CANCER; VIRUS DETECTION; WART VIRUS; ANTIBODY SPECIFICITY; BLOOD; CLASSIFICATION; DNA SEQUENCE; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; PAPILLOMA VIRUS; SERODIAGNOSIS; VIROLOGY; VIRUS INFECTION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CHINA; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SEQUENCE ANALYSIS, DNA;

EID: 62849098793     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21435     Document Type: Article

References (30)

1. Baay MF, Tjalma WA, Weyler J, Goovaerts G, Buytaert P, Van Marck EA, Lardon F, Vermorken JB. 2001. Human papillomavirus infection in the female population ofAntwerp, Belgium: Prevalence in healthy women, women with premalignant lesions and cervical cancer. Eur J Gynaecol Oncol 22:204-208.
2. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. 1995. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796-802.
3. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2004. Efficient intracellular assembly of papillomaviral vectors. J Virol 78:751-757.
4. Carter JJ, Galloway DA. 1997. Humoral immune response to human papillomavirus infection. Clin Dermatol 15:249-259.
5. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. 2000. Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. J Infect Dis 181:1911 -1919.
6. Chan PK, Li WH, Chan MY, Ma WL, Cheung JL, Cheng AF. 1999. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J Med Virol 59:232-238.
7. Christensen ND, Kreider JW, Shah KV, Rando RF. 1992. Detection of human serum antibodies that neutralize infectious human papillo- mavirus type 11 virions. J Gen Virol 73:1261 -1267.
8. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur H. 2004. Classification of papillomaviruses. Virology 324:17-27.
9. Ferrera A, Velema JP, Figueroa M, Bulnes R, Toro LA, Claros JM, De BO, Melchers WJ. 1999. Human papillomavirus infection, cervical dysplasia and invasive cervical cancer in Honduras: A case-control study. Int J Cancer 82:799-803.
10. Gissmann L. 1996. Immunologic responses to human papillomavirus infection. Obstet Gynecol Clin North Am 23:625-639.
11. Hagensee ME, Yaegashi N, Galloway DA. 1993. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 67:315-322.
12. Ho GY, Studentsov YY, Bierman R, Burk RD. 2004. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13:110 -116.
13. Huang S, Afonina I, Miller BA, Beckmann AM. 1997. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 70:408-411.
14. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. 1998. In vitro construction of pseudovirions of human papillomavirus type 16: Incorporation ofplasmid DNA into reassembled L1/L2 capsids. J Virol 72:10298-10300.
15. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. 1992. Papillomavirus L1 major capsid protein self-assembles into viruslike particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180-12184.
16. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645-1651. Lo KW, Wong YF, Chan MK, Li JC, Poon JS, Wang VW, Zhu SN, Zhang TM, He ZG, Wu QL, Li GD, Tam JS, Kahn T, Lam P, Cheung TH, Chung TK. 2002. Prevalence of human papillomavirus in cervical cancer: A multicenter study in China. Int J Cancer 100:327-331.
17. Longuet M, Beaudenon S, Orth G. 1996. Two novel genital human papillomavirus (HPV) types, HPV68 and HPV70, related to the potentially oncogenic HPV39. J Clin Microbiol 34:738-744.
18. Lowy DR, Schiller JT. 1998. Papillomaviruses and cervical cancer: Pathogenesis and vaccine development. J Natl Cancer Inst Monogr 1998:27-30.
19. Munoz N, Bosch FX, Castellsague X, Diaz M, De SS, Hammouda D, Shah KV, Meijer CJ. 2004. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111:278-285.
20. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kruger KS, Lowy DR, Schiller JT. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papilloma- virus neutralization assay for HPV16 and HPV18. Virology 321:205-216.
21. Reuter S, Delius H, Kahn T, Hofmann B, zur Hausen H, Schwarz E. 1991. Characterization of a novel human papillomavirus DNA in the cervical carcinoma cell line ME180. J Virol 65:5564-5568.
22. Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT. 1996. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 70:5875-5883.
23. Schellekens MC, Dijkman A, Aziz MF, Siregar B, Cornain S, Kolkman- Uljee S, Peters LA, Fleuren GJ. 2004. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol 93:49-53.
24. Sigurdsson K, Taddeo FJ, Benediktsdottir KR, Olafsdottir K, Sigval- dason H, Oddsson K, Rafnar T. 2007. HPV genotypes in CIN2-3 lesions and cervical cancer: A population-based study. Int J Cancer 121:2682-2687.
25. Smith LH, Foster C, Hitchcock ME, Leiserowitz GS, Hall K, Isseroff R, Christensen ND, Kreider JW. 1995. Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro. J Invest Dermatol 105:438-444.
26. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
27. Woodman CB, Collins SI, Young LS. 2007. The natural history of cervical HPV infection: Unresolved issues. Nat Rev Cancer 7: 11 - 22.
28. Zhou J, Sun XY, Stenzel DJ, Frazer IH. 1991. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185:251 -257.
29. zur Hausen H. 1991. Viruses in human cancers. Science 254:1167-1173.
30. zur Hausen H, de Villiers EM. 1994. Human papillomaviruses. Annu Rev Microbiol 48:427-447.